Reports
Reports
The global prothrombin complex concentrate (PCC) market is expected to grow at a CAGR of about 9% in the forecast period of 2023-2028.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Europe will be among of the leading regions for prothrombin complex concentrate (PCC) owing to its clinical advantage over fresh frozen plasma. With the advent of Covid-19, there has been an increase in the demand for the PCC. It is because of the noticeable success of plasma-based therapies in the patients. The Asia Pacific region is also expected to rise rapidly with the adoption of Kcentra which was approved by the United States Food and Drug Administration (FDA). The market is also expected to be developed in Latin America and Middle East and Africa with the increased spending on healthcare and improvement of distribution mechanisms.
Prothrombin complex concentrate (PCC) is produced from human plasma and used as a medication comprising blood clotting. It is utilised in the treatment of hemophilia to prevent bleeding. Vitamin K antagonist treatment also accompanies the usage of PCC when acute bleeding occurs. This is listed as one of the safest and most effective medicine in World Health Organisation’s list of essential medicines required in health system.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
PCC can be divided on the basis of product into:
On the basis of application, PCC can be divided into:
PCC finds its end use in the following:
The regional markets for PCC can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
PCC is expected to have a significant rise because of its clinical advantage against fresh frozen plasma (FPP). PCC needs less volume and infusion time when compared to FFP and is more effective. PCC also does not require blood matching and thawing like FFP. The widespread use of Vitamin K antagonist like warfarin is also expected to drive robust industry growth for PCC. According to FDA, the adult patients undergoing Vitamin K antagonist treatment can have acquired coagulation factor deficiency. In case of acute bleeding, the urgent reversal for such can be done with the indication of PCC, Kcentra. Hemophilic patients are expected to increase in number over upcoming years. Their treatment requires PCC which will further boost the demand. The recent government policies have also worked in the favour for PCC with the relaxation in its usage approval. Government funding has also promoted the use of PCC for bleeding control. COVID-19 has seen rise in plasma related therapies which has rapidly increased PCC demand. Plasma collection centres have been set up by key players to stock up blood demand in PCC.
The report gives a detailed analysis of the following key players in the global prothrombin complex concentrate (PCC) market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
REPORT FEATURES | DETAILS |
---|---|
Base Year | 2022 |
Historical Period | 2018-2022 |
Forecast Period | 2023-2028 |
Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Product, Application, End Use, Region |
Breakup by Product | 3-Factor PCC, 4-Factor PCC, Others |
Breakup by Application | Acquired Coagulation Factor Deficiency, Congenital Coagulation Factor Deficiency, Others |
Breakup by End Use | Hospitals, Ambulatory Surgical Centres, Others |
Breakup by Region | North America, Latin America, Europe, Middle East and Africa, Asia Pacific |
Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
Companies Covered | CSL Behring GmbH, Octapharma AG, Kedrion S.p.A, Others |
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Prothrombin Complex Concentrate (PCC) Market Analysis
8.1 Key Industry Highlights
8.2 Global Prothrombin Complex Concentrate (PCC) Historical Market (2018-2022)
8.3 Global Prothrombin Complex Concentrate (PCC) Market Forecast (2023-2028)
8.4 Global Prothrombin Complex Concentrate (PCC) Market by Product
8.4.1 3-Factor PCC
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 4-Factor PCC
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Others
8.5 Global Prothrombin Complex Concentrate (PCC) Market by Application
8.5.1 Acquired Coagulation Factor Deficiency
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Congenital Coagulation Factor Deficiency
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Others
8.6 Global Prothrombin Complex Concentrate (PCC) Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Ambulatory Surgical Centres
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Others
8.7 Global Prothrombin Complex Concentrate (PCC) Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2022)
8.7.4.3 Forecast Trend (2023-2028)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2022)
8.7.5.3 Forecast Trend (2023-2028)
9 North America Prothrombin Complex Concentrate (PCC) Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Prothrombin Complex Concentrate (PCC) Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Prothrombin Complex Concentrate (PCC) Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Prothrombin Complex Concentrate (PCC) Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa Prothrombin Complex Concentrate (PCC) Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 CSL Behring GmbH
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Octapharma AG
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 Kedrion S.p.A
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Prothrombin Complex Concentrate (PCC) Market: Key Industry Highlights, 2018 and 2028
2. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Product (USD Billion), 2018-2022
3. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Product (USD Billion), 2023-2028
4. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Application (USD Billion), 2018-2022
5. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Application (USD Billion), 2023-2028
6. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by End Use (USD Billion), 2018-2022
7. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by End Use (USD Billion), 2023-2028
8. Global Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Region (USD Billion), 2018-2022
9. Global Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Region (USD Billion), 2023-2028
10. North America Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2018-2022
11. North America Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2023-2028
12. Europe Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2018-2022
13. Europe Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Asia Pacific Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Asia Pacific Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Latin America Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2018-2022
17. Latin America Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2023-2028
18. Middle East and Africa Prothrombin Complex Concentrate (PCC) Historical Market: Breakup by Country (USD Billion), 2018-2022
19. Middle East and Africa Prothrombin Complex Concentrate (PCC) Market Forecast: Breakup by Country (USD Billion), 2023-2028
20. Global Prothrombin Complex Concentrate (PCC) Market Structure
The global prothrombin complex concentrate (PCC) market is projected to grow at a CAGR of 9% between 2023 and 2028.
The major trends augmenting the market’s growth are the expected rise in the number of haemophilic patients, growth in government initiatives, rising need for plasma related therapies due to COVID-19, increased spending on healthcare, and improvement of distribution mechanisms.
The key trends propelling the market forward are the widespread use of vitamin K antagonists like warfarin and the clinical advantage of PCC over fresh frozen plasma.
The major regions in the industry are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific with North America and Europe accounting for the largest share in the market.
PCC can be divided on the basis of product into 3-factor PCC and 4-factor PCC, among others.
On the basis of application, PCC can be divided into acquired coagulation factor deficiency and congenital coagulation factor deficiency, among others.
The end-uses are Hospitals and ambulatory surgical centres, among others.
The major players in the industry are CSL Behring GmbH, Octapharma AG, and Kedrion S.p.A, among others.
The global prothrombin complex concentrate (PCC) market is being driven by the clinical advantage of PCC over fresh frozen plasma in the historical period. Aided by the widespread use of vitamin K antagonists like warfarin and the expected rise in the number of hemophilic patients, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 9%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its product types, the global prothrombin complex concentrate (PCC) industry can be segmented into 3-factor PCC and 4-factor PCC, among others. By application, acquired coagulation factor deficiency and congenital coagulation factor deficiency, among others are the various segments. On the basis of end-use, hospitals and ambulatory surgical centres, among others are the major sectors. The major regional markets for prothrombin complex concentrate (PCC) are North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific, with North America and Europe accounting for the largest share of the market. The key players in the above market include CSL Behring GmbH, Octapharma AG, and Kedrion S.p.A, among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.